Innate Pharma (IPH) Corporate presentation summary

Strategic focus and portfolio overview

• Concentrates on three high-value clinical assets: lacutamab, IPH4502, and monalizumab, each targeting significant unmet needs in oncology.

• In-house expertise enables discovery and development of differentiated antibody therapeutics.

• Organization is streamlined for agile execution and impact in oncology markets.

Lacutamab: clinical progress and market opportunity

• Lacutamab targets KIR3DL2 in CTCL and PTCL, showing durable activity and favorable tolerability in Phase 2 trials.

• Phase 3 TELLOMAK-3 trial in CTCL (MF and SS) cleared by FDA, with potential for accelerated approval in SS by 2027.

• Demonstrated strong clinical benefit in heavily pre-treated Sézary syndrome and mycosis fungoides patients, including post-mogamulizumab.

• Positioned as a preferred systemic therapy in NCCN guidelines and projected to exceed $500m in peak annual sales.

• Commercial launch in the US is accessible due to patient concentration in top academic centers.

IPH4502: innovation in solid tumors

• IPH4502 is a novel Nectin-4 exatecan ADC with a differentiated design to overcome resistance and toxicity seen with current therapies.

• Preclinical data show activity in bladder cancer post-enfortumab vedotin and across multiple solid tumors with low-to-moderate Nectin-4 expression.

• Phase 1 trial in advanced solid tumors is nearing completion of dose escalation and cohort enrichment.

• Addresses a significant therapeutic gap for patients progressing after EV + pembrolizumab in bladder cancer.